Resona Asset Management Co. Ltd. Reduces Holdings in Waters Corporation $WAT

Resona Asset Management Co. Ltd. reduced its stake in shares of Waters Corporation (NYSE:WAT) by 6.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,235 shares of the medical instruments supplier’s stock after selling 1,862 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Waters were worth $10,926,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Pinnacle Associates Ltd. grew its holdings in Waters by 0.3% during the 4th quarter. Pinnacle Associates Ltd. now owns 7,608 shares of the medical instruments supplier’s stock valued at $2,890,000 after buying an additional 26 shares during the last quarter. Exencial Wealth Advisors LLC raised its holdings in shares of Waters by 1.7% in the fourth quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier’s stock worth $638,000 after acquiring an additional 28 shares during the last quarter. Clearstead Advisors LLC raised its holdings in shares of Waters by 5.1% in the fourth quarter. Clearstead Advisors LLC now owns 616 shares of the medical instruments supplier’s stock worth $234,000 after acquiring an additional 30 shares during the last quarter. Avalon Trust Co lifted its position in shares of Waters by 2.3% in the first quarter. Avalon Trust Co now owns 1,330 shares of the medical instruments supplier’s stock valued at $396,000 after acquiring an additional 30 shares in the last quarter. Finally, Integrated Wealth Concepts LLC lifted its position in shares of Waters by 2.9% in the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after acquiring an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Insider Activity at Waters

In other news, Director Christopher A. Kuebler sold 3,626 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the transaction, the director directly owned 17,808 shares in the company, valued at $7,086,515.52. This represents a 16.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.31% of the stock is currently owned by corporate insiders.

Waters Price Performance

Shares of NYSE:WAT opened at $414.90 on Friday. The company has a market cap of $40.76 billion, a P/E ratio of 103.47, a P/E/G ratio of 2.42 and a beta of 1.19. The business has a fifty day simple moving average of $376.26 and a 200-day simple moving average of $345.85. Waters Corporation has a 52 week low of $282.77 and a 52 week high of $420.26. The company has a quick ratio of 0.50, a current ratio of 0.77 and a debt-to-equity ratio of 0.32.

Waters (NYSE:WAT) last released its earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, topping the consensus estimate of $3.01 by $0.04. Waters had a return on equity of 11.27% and a net margin of 3.58%.The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.62 billion. During the same period in the prior year, the business posted $2.95 earnings per share. The firm’s revenue for the quarter was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Equities research analysts forecast that Waters Corporation will post 14.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Morgan Stanley set a $430.00 price objective on Waters in a research report on Wednesday, August 5th. Bank of America upped their target price on shares of Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a report on Tuesday, June 2nd. Weiss Ratings cut shares of Waters from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday. Royal Bank Of Canada lifted their price target on shares of Waters from $435.00 to $475.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, HSBC boosted their price objective on shares of Waters from $415.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, June 3rd. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Waters presently has a consensus rating of “Moderate Buy” and a consensus target price of $420.35.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.